In final guidance released Thursday on naming of Biologic drugs, FDA reiterated that each biologic should receive a non-proprietary "core name" plus a unique four-letter suffix that is devoid of meaning. Each biologic and biosimilar would receive a hyphenated "proper name" joining the core name with the suffix.
This post first appeared on Drugwonks | Welcome To The New Drugwonks.com, please read the originial post: here